PDE5A and arthritic joint disease: The larger groups showing promise included cerebrovascular modulators (antihypertensives, vasodilators, PDE5 inhibitors, antiplatelet, antimigraine), immunomodulators (antihistamine, non‐steroidal anti‐inflammatory drugs [NSAIDs], antivirals, antigout, and anti‐arthritis) and metabolic stimulators, coenzymes, antioxidants, and vitamins.